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Introduction
Smoking is considered to be one of the primary etio-
logical factors of many respiratory diseases, the most serious
of which are chronic obstructive pulmonary diseases
(COPD) and lung carcinoma (LC). Cigarette smokers have a
higher mortality rate due to LC and COPD than non-smokers
1. Tobacco smoke is a complex mixture of over 4 700 chemi-
cal compounds, including high concentrations of oxidant
agents, capable of interacting with cell constituents. Free
radicals are atoms or molecules containg an impair number
of electrons, which results in an unpaired electrons in the
external orbit. In the human, oxygen, by means of its de-
rivates referred to as reactive oxygen species acts as the fun-
damental oxidant. Once produced, these reactive metabolites
can alter cellular and metabolic structures, interact with
membrane unsaturated fatty acids, thus modifying the DNA
and giving rise to mutations, with proteins and polysaccha-
rides, creating more or less substantial alterations 
2.
Tobacco smoke and oxidative stress
All the individuals by the physiological breathing pro-
cess produce free radicals. Oxidant – antioxidant balance in
our organism is not stabile and many factors, such as to-
bacco smoke, infections, chemicals in environmental pol-
lution can unbalance it, which result in the appearance of
oxidative stress (Figure 1) 
3. Oxidative stress can be de-
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fined as an increased exposure to oxidants and/or a reduced
defensive ability of the antioxidants 
2. The outcome of this
condition at molecular level is an attack on various cell
constituents ending in their irreversible damage and, con-
sequently, damage to the cell structures and functions 
1.
The human organism which is constantly attacked by dam-
aging compounds in air, actuated mechanisms for defend-
ing and cleaning the lungs, which exert their action primar-
ily against oxidant substances. Main natural antioxidants
are: tracheobronchial mucus, alveolar lining, endocellular
enzymatic substances (superoxide dismutase, catalase,
gluthatione peroxidase, glutatione reductase), membrane
scavengers (vitamine E, beta carotene), extracellular anti-
oxidants (plasma proteins – albumin, ceruloplasmin, trans-
ferrin, alfa 1 – antitrypsin; low molecular weight scaven-
gens – bilirubin, methionine, uric acid; glutathione, cata-
lase, superoxide – dismutase, vitamin C, vitamin E) 
1, 3.
When natural antioxidants are ineffective, oxidative stress
appears and it results in many respiratory disorders, in-
cluding first and foremost COPD, LC and pulmonary fibro-
sis 
4.
Free radicals in smoke are present both in the gas –
phase and in the particulate phase (tar). The inhaled gas
components contain approximately 10 
15 radicals per puff
(primarly alkyl and peroxyl types). Nitric oxide (NO), a free
radical physiologically produced by the organism following
antigenic stimulation, is also present in cigarette smoke. This
compound reacts quickly with the superoxide anion (O2) to
form peroxynitrite and with peroxyl radicals to form alkyl
peroxynitrites.
Whereas short lived radicals in the gas – phase of ciga-
rette smoke can be inactivated immediately in the epithelial
lining fluid (ELF), redox reactions in cigarette smoke con-
densate, which forms in the ELF, can produce reactive oxy-
gen species for a considerable period 
5.
Tobacco smoke causes the burst of inflammatory cells
expecially neutrophils, which in turn increase the quantity of
oxidants in the airways. Moreover an alveolar macrophage
and neutrophil accumulation has been observed in the lungs
of smokers.
Smoking, oxidative stress and chronic obstructive
pulmonary diseases
Oxidative stress plays a pathogenic role of primary im-
portance in COPD 
6.
The clinical manifestations of COPD are influenced by
a number of risk factors including alpha-1-antitrypsin defi-
ciency, low birth weight, air pollution, socio-economic
status, recurrent respiratory infections and tobacco smoke,
which plays a leading role (Figure 2) 
1, 7. About 90% of all
COPD patients are smokers or ex-smokers. They are chroni-
cally exposed to exogenous oxidant overloads and have
chronic bronchial inflammation with an increase and activa-
tion of macrophages and neutrophil granulocytes. These in-
flammatory cells, by damaging oxidant compounds forma-
tion, inhibit the antiprotease defence systems and alter mu-
cociliary clearance, leading to the known patho-anatomical
and functional transformations 
1.
It is possible to identify several oxidative stress indicators
in smokers with COPD 
1. Since oxygen radicals direct measur-
ment is difficult in lung tissue or in exhaled air, an alternative is
to measure the biomolecules involved in a free radical damage
such as lipids and hydrogen peroxide (H2O2). Patients with
COPD have a chronic formation of oxygen radicals in the lung,
which can be measured by means of the H2O2 in exhaled air.
Alveolar macrophages from smokers release significantly more
superoxide anion when compared to healthy controls.
Free radicals also trigger a lipid peroxidation chain re-
action. The resulting lipid radical reacts with oxygen to
Fig. 2 − Schematization of the processes causing pulmonary oxidative damage that contributes in different
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make a peroxyl radical, which then transforms polyunsatu-
rated fatty acid into lipid hydroperoxides, capable of pro-
ducing other radical compounds. Lipid peroxidation can
impair membrane function, increase membrane permeabil-
ity and inactivate membrane  –  bound receptors and en-
zymes 
8.
Oxidant radicals in lung cancer
Lung cancer arises as a focal transformation of chroni-
cally injured epithelium by different factors, the most well –
known of which is tobacco smoke. One of the most signifi-
cant effects of oxygen radicals is DNA damage. Different
compounds in tobacco smoke can react directly to form radi-
cals, while other substances are pre-carcinogens and need to
be activated by one or more of the P450 cytochromes 
9.
Gackowski, et al. 
10, confirmed significantly higher val-
ues of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodGuo) in
leukocyte DNA in smokers with LC and ex-smokers with LC
than in healthy smokers and healthy nonsmokers. The mean
levels of vitamin C in the plasma is significantly higher in
healthy nonsmokers than in smokers with LC. Vitamin E, as
measured antioxidant in plasma, was reduced in patients with
LC (smokers or ex-smokers) compared to healthy smokers.
Their results suggest that a high level of 8-oxodGuo in leu-
kocyte DNA and low concentration of vitamin E in blood
may predict lung cancer risk.
In another study, authors measured oxidative DNA
damage biomarkers (urinary excretion of 8-hydroxy-2'-
deoxyguanosine = 8-OH-dGuo and 8-hydroxyguanine = 8-
OH-Gua) in LC patients who were smokers, healthy smokers
and healthy nonsmokers. The mean level of biomarkers in
urine was significantly lower in nonsmokers than in smoker
groups (cancer patients and healthy smokers) 
11. 
Paz-Elizur, et al. 
12 investigated the activity of DNA re-
pair enzyme 8-oxoguanine DNA N-glucosylase (OGG)
which repairs the oxidative DNA lesion 8-oxoguanine in pa-
tients with LC. They measured low OGG activity in patients
with LC. They concluded that low OGG activity is associ-
ated with an increased risk of LC. Authors suggested that
smoking cessation in individuals with reduced OGG activity
might be an effective strategy in LC prevention.
Oxidative stress in interstitial lung disease
There were an oxidant-antioxidant inbalance also in the
pathogenesis of interstitial lung diseases 
13. Idiopathic pulmo-
nary fibrosis is characterised by alveolitis with accumulation
of macrophages and neutrophils, which preceedes injury to the
lung parenchima. In pulmonary fibrosis glutathion deficiency
occurs in the alveolar lavage fluid, which further contributes to
determine and explain oxidative cell damage 
14. There are in-
creases in the number of inflammatory cells and they release
large amounts of highly reactive oxygen free radicals.
The study confirmed that there was a reduced glutathi-
one concentration in the ELF of patients with idiopathic
pulmonary fibrosis 
14. Levels were increased following the
treatment with oral N-acetylcystein. The significance of this
study is based on increasing glutathion levels in order to en-
hance the antioxidant protection of the lung and the control
of the proliferation of fibroblasts.
Conclusion
Tobacco smoke is one of the well-known risk factors
for oxidative stress which plays an important pathogenic role
in the appearance of various pulmonary diseases including
first and foremost COPD, LC and pulmonary fibrosis.
REFERENCES
1.  Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic ob-
structive pulmonary disease. Oxidative Stress Study Group.
Am J Respir Crit Care Med 1997; 156(2 Pt 1): 341−57.
2.  Baskin SI, Salem H. Oxidants, antioxidants and free radicals.
Washington: Taylor and Francis; 1997.
3.  Repine JE, Heffner JE. Lung antioxidants. In: Crystal RG, West
JB, Weibel PJ, Barnes PJ, editors. The lung: scientific founda-
tions. Philadelphia: Lippincott − Raven; 1997. p. 2259−69.
4.  Halliwell B. Antioxidants in human health and disease. Annu
Rev Nutr 1996; 16: 33−50.
5.  Ghio AJ, Stonehuerner J, Quigley DR. Humic-like substances in
cigarette smoke condensate and lung tissue of smokers. Am J
Physiol 1994; 266(4 Pt 1): L382−8.
6.  Macnee W, Rahman I. Oxidants and antioxidants as therapeutic
targets in chronic obstructive pulmonary disease. Am J Respir
Crit Care Med 1999; 160(5 Pt 2): S58−65.
7.  Buist AS. Risk factors for COPD. Eur Respir Rev 1996; 6(39):
253−8.
8.  Halliwell B, Chirico S. Lipid peroxidation: its mechanism, meas-
urement, and significance. Am J Clin Nutr 1993; 57(5 Suppl):
715S−724S.
9.  van Zandwijk N. N-acetylcysteine for lung cancer prevention.
Chest 1995; 107(5): 1437−41.
10. Gackowski D, Kowalewski J, Siomek A, Olinski R. Oxidative
DNA damage and antioxidant vitamin level: comparison
among lung cancer patients, healthy smokers and nonsmokers.
Int J Cancer 2005; 114(1): 153−6.
11. Gackowski D, Speina E, Zielinska M, Kowalewski J, Rozalski R, Si-
omek A, et al. Products of oxidative DNA damage and repair
as possible biomarkers of susceptibility to lung cancer. Cancer
Res 2003; 63(16): 4899−902.
12. Paz-Elizur T, Krupsky M, Blumenstein S, Elinger D, Schechtman E,
Livneh Z. DNA repair activity for oxidative damage and risk of
lung cancer. J Natl Cancer Inst 2003; 95(17): 1312−9.
13. Meyer A, Buhl R, Kampf S, Magnussen H. Intravenous N-
acetylcysteine and lung glutathione of patients with pulmonary
fibrosis and normals. Am J Respir Crit Care Med 1995; 152(3):
1055−60.
14. Meyer A, Buhl R, Magnussen H. The effect of oral N-
acetylcysteine on lung glutathione levels in idiopathic pulmo-
nary fibrosis. Eur Respir J 1994; 7(3): 431−6.
The paper was received on March 27, 2006. 